================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
March 31, 2005
TRANSGENOMIC, INC.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-30975 911789357
------------------------ ------------------------ ----------------------
(State of Incorporation) (Commission File Number) (IRS Employer
Identification Number)
12325 Emmet Street, Omaha, Nebraska 68164
------------------------------------------ ----------
(Address of principal executive offices) (Zip Code)
(402) 452-5400
----------------------------------------------------
(Registrant's telephone number, including area code)
Not applicable
-------------------------------------------------------------
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On March 31, 2005, Transgenomic, Inc. issued a press release announcing
its financial results for the fourth quarter of 2004. A copy of the press
release is being furnished herewith as Exhibit 99.1 to this Current Report on
Form 8-K.
The information referenced in this Current Report on Form 8-K (including
Exhibit 99 referenced in Item 9.01 below) is being `furnished" under "Item 2.02.
Results of Operations and Financial Condition" and, as such, shall not be deemed
to be "filed" for the purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities
of that Section. The information set forth in this Current Report on Form 8-K
(including Exhibit 99 referenced in Item 9.01 below) shall not be incorporated
by reference into any registration statement or other document pursuant to the
Securities Act of 1933, as amended (the "Securities Act"), except as shall be
expressly set forth by specific reference in such filing.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits.
(99) Press release dated March 31, 2005, announcing Transgenomic, Inc.'s
financial results for the fourth quarter of 2004.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Dated: March 31, 2005 TRANSGENOMIC, INC.
By: /s/ Michael Summers
----------------------
Michael Summers,
Chief Financial Officer